| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 3, June 24（Tue.）
Room P (Maesato East, Foyer, Ocean Wing)
- 3P-AM-09
A Novel Approach for Quantifying Therapeutic Monoclonal Antibodies in Blood through Liquid Chromatography–Tandem Mass Spectrometry
(1NTUH, 2NTU)
oHuai-Hsuan Chiu1, Tsun-Hao Chi2, Chiao Lo1, Shin-Yi Lin1, Ching-Hua Kuo2
Therapeutic monoclonal antibodies (mAbs) are increasingly used in clinical applications, but suboptimal treatment outcomes highlight the need for therapeutic drug monitoring (TDM) with personalized dosing. Volumetric absorptive microsampling (VAMS) allows for easy collection of small, fixed-volume blood samples, yet its feasibility for TDM of mAbs remains underexplored.
In this study, we developed and optimized an analytical method to quantify three mAbs including trastuzumab, pembrolizumab, and bevacizumab in VAMS. A 10-minute extraction was identified as the optimal condition, yielding recovery rates exceeding 82.3%. We also confirmed that ethylenediaminetetraacetic acid (EDTA) does not affect trypsin digestion, eliminating potential quantification bias when using whole blood for calibration. Method accuracy ranged from 97.8% to 115.3%, with intraday and interday precision RSDs below 7.4%. In addition, the three tested mAbs remained stable for 30 days at room temperature in VAMS. Furthermore, we identified a strong correlation between mAb concentrations in plasma and VAMS.
Finally, the method was applied to breast cancer patients receiving trastuzumab, demonstrating its potential for clinical TDM. These findings support VAMS as a practical tool for advancing personalized medicine. The newly developed method exhibits promise for clinical use by simplifying the intricacies of intravenous sampling for determining mAb concentrations.